Relevant bibliographies by topics / QU 7.5 UL

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'QU 7.5 UL'

Author: Grafiati
Published: 4 June 2021
Last updated: 17 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'QU 7.5 UL.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "QU 7.5 UL"

1

O’Fallon, Kevin S., Diksha Kaushik, Bozena Michniak-Kohn, C. Patrick Dunne, Edward J. Zambraski, and Priscilla M. Clarkson. "Effects of Quercetin Supplementation on Markers of Muscle Damage and Inflammation after Eccentric Exercise." International Journal of Sport Nutrition and Exercise Metabolism 22, no. 6 (2012): 430–37. http://dx.doi.org/10.1123/ijsnem.22.6.430.

Full text
Abstract:
The flavonoid quercetin is purported to have potent antioxidant and anti-inflammatory properties. This study examined if quercetin supplementation attenuates indicators of exercise-induced muscle damage in a doubleblind laboratory study. Thirty healthy subjects were randomized to quercetin (QU) or placebo (PL) supplementation and performed 2 separate sessions of 24 eccentric contractions of the elbow flexors. Muscle strength, soreness, resting arm angle, upper arm swelling, serum creatine kinase (CK) activity, plasma quercetin (PQ), interleukin-6 (IL-6), and C-reactive protein (CRP) were assessed before and for 5 d after exercise. Subjects then ingested nutrition bars containing 1,000 mg/d QU or PL for 7 d before and 5 d after the second exercise session, using the opposite arm. PQ reached 202 ± 52 ng/ml after 7 d of supplementation and remained elevated during the 5-d postexercise recovery period (p < .05). Subjects experienced strength loss (peak = 47%), muscle soreness (peak = 39 ± 6 mm), reduced arm angle (–7° ± 1°), CK elevations (peak = 3,307 ± 1,481 U/L), and arm swelling (peak = 11 ± 2 mm; p < .0001), indicating muscle damage and inflammation; however, differences between treatments were not detected. Eccentric exercise did not alter plasma IL-6 (peak = 1.9 pg/ml) or CRP (peak = 1.6 mg/L) relative to baseline or by treatment. QU supplementation had no effect on markers of muscle damage or inflammation after eccentric exercise of the elbow flexors.
APA, Harvard, Vancouver, ISO, and other styles
2

Dionne*, Jean-Claude. "Données complémentaires sur la transgression laurentienne, à Montmagny (Québec), à partir d’une coupe dans la partie arrière de la terrasse de 8-10 mètres." Géographie physique et Quaternaire 57, no. 2-3 (2005): 249–53. http://dx.doi.org/10.7202/011319ar.

Full text
Abstract:
Résumé Une excavation récente, d’environ 6 m de profondeur, a permis d’observer les unités lithostratigraphiques composant la partie arrière de la terrasse de 8-10 m, entre Montmagny et Cap-Saint-Ignace. On y a trouvé 3 des 5 unités exposées dans la falaise vive, à l’extrémité est de l’aéroport. Les unités manquantes sont le dépôt infratidal limono-argileux daté de 8 à 7 ka et la couche organique datée de 7 à 6 ka. Dans la partie arrière de la terrasse de 8-10 m, l’argile de la Mer de Goldthwait, qui est à une altitude d’environ 5 m, en comparaison de 1 m au droit de la falaise vive, est surmontée d’une couche de sable et gravier d’une trentaine de centimètres d’épaisseur. Un fragment de bois au sommet de cette unité a donné un âge au 14C de 5970 ± 70 BP (UL-2737). Cette couche grossière est recouverte d’environ 3 m de rythmites tidales limono-sableuses contenant d’abondants débris de plantes aquatiques in situ qui ont donné un âge de 5460 ± 70 BP (UL-2719), alors que deux fragments de bois à la base de l’unité ont été datés respectivement à 5640 ± 70 (UL-2735) et 5650 ± 70 BP (UL-2718). L’unité intertidale mise en place lors de la transgression de l’Holocène moyen est coiffée par une tourbière d’une soixantaine de centimètres d’épaisseur. La base de cette dernière a donné un âge au 14C de 5080 ± 60 BP (UL-2740) pour la tourbe et de 5020 ± 70 BP (UL-2737) pour une souche de mélèze (Larix sp.). Cette coupe confirme donc l’étendue et l’altitude de la Transgression laurentienne dans le secteur entre la rivière du Sud, à Montmagny, et Cap-Saint-Ignace.
APA, Harvard, Vancouver, ISO, and other styles
3

Sirachainan, Nongnuch, Usanarat Anurathapan, Ampaiwan Chuansumrit, et al. "Outcome of Intramuscular Anti-D In Children with Chronic Immune Thrombocytopenia (ITP) and Severe Thrombocytopenia: A Case-Control Study,." Blood 118, no. 21 (2011): 3285. http://dx.doi.org/10.1182/blood.v118.21.3285.3285.

Full text
Abstract:
Abstract Abstract 3285 Introduction: Chronic ITP accounts for 20–30% of children with ITP. Treatment includes immunosuppressive agents and splenectomy to maintain platelet count above 20,000/uL. The limitation of treatment was the risk of infection and malignancy. Intravenous anti-D showed some effectiveness in patients with acute and chronic ITP; however, this medication is unavailable in some countries. Objective: To determine the effectiveness and outcome of intramuscular anti-D in children with chronic ITP. Methods: Patients, children age≤18 years, diagnosed with chronic ITP with platelet count <20,000/uL, were enrolled. Treatment protocol, intramuscular anti-D (Igamed®) of 10 mcg/kg/dose, was divided into 3 phases of varied regimens: phase I - anti-D daily for 5 days; phase II - anti-D weekly for 12 weeks and withheld when platelet counts ≥20,000/uL; and phase III - anti-D once every 2 weeks for 24 weeks. Direct Coombs' test and LDH and hemoglobin (Hb) levels were monitored on day 3, 5 and 7 during phase I; every week during phase II and every 2 weeks during phase III. The response was defined by platelet count>20,000/uL. Results: Twenty-five patients with chronic ITP, median (range) age 7.8(3.8–15.5) years, were enrolled, 9 patients [median age 11.3(4.6–15.5) years, females:males = 2:7] were treated with anti-D while 16 patients [median age 6.6(3.8–12.3) years, females:males = 4:12] were not. Median platelet count at the time of enrollment was 7,000(2,000–18,000)/uL. Median platelet counts in anti-D treatment [9,000(2,000–18,000)/uL] and non-treatment [4,500(2,000–16,000)/uL] groups at the time of enrollment were not significantly different. During phase I, the median platelet counts in all treated patients significantly increased from 9,000(6,500–14,700)/uL to 32,000(22,430–46,000)/uL, p= 0.012. The maximum response was during days 4–5 after treatment. Seven patients received anti-D weekly in phase II and every 2 weeks in phase III with a total of 84 episodes each in both phases. The results revealed platelet count≥ 20,000/uL in 21 episodes [25(8.3–78.2)%] in phase II and 25.5 episodes [30.7(0–50)%] in phase III. Direct Coombs' tests were positive (3+ to 4+) in all patients; however, Hb level was not changed. The median follow-up time after enrollment in anti-D treatment group was 2.2(0.6–3.7) years. One patient in anti-D treatment group was in remission (platelet>100,000/uL) at 1.3 and 0.8 years after diagnosis and enrollment, respectively and 8 patients in non-treatment group were in remission at median time of 4.1(1.6–5.4) and 2.0(0.8–4.2) years after diagnosis and enrollment, respectively, p= 0.22. Conclusion: Intramuscular anti-D demonstrated the 100% response when given 10 mcg/kg/dose for 5 days. The once a week and once every 2 weeks showed only 25% and 30% response, respectively. Anti-D treatment during 37 weeks did not affect the long-term outcome. No complication was detected. Therefore, intramuscular anti-D given 10 mcg/kg for 5 days can be an alternative method to raise platelet count for immediate invasive procedure requirement in chronic ITP patients with severe thrombocytopenia. Disclosures: No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
4

Pasaribu, Syarifah Aini, M. Rizqy Darojat, and Ernita Bukit. "Teknologi Perakitan Klon Karet Unggul dengan Komponen Biayanya." Talenta Conference Series: Agricultural and Natural Resources (ANR) 1, no. 1 (2018): 42–46. http://dx.doi.org/10.32734/anr.v1i1.94.

Full text
Abstract:
Perakitan klon karet unggul terus menerus dilakukan sejak tahun 1980-an di Balai Penelitian Sungei Putih, Pusat Penelitian Karet. Teknik perakitan dilakukan secara konvensional dengan persilangan alami dan buatan. Setelah itu dilakukan seleksi, pengujian pendahuluan, pengujian lanjutan, dan pengujian adaptasi. Tujuan perakitan adalah mendapatkan klonyang memiliki potensi hasil dan sifat-sifat agronomis lebih baik dari padaklon saat ini. Keunggulan suatu klon ditentukan oleh faktor genetik yang dikandungnya dan diekspresikan dalam bentuk morfologis, susunan anatomis dan proses fisiologis yang menunjang pertumbuhan, potensi hasil dan daya adaptasi terhadap lingkungan. Sepuluh tahun terakhir (2006 s.d 2015), total bunga yang disilangkan adalah 224.248 bunga, dengan jumlah tanaman F1 sebanyak 2.451 genotipe. Kebun F1 terbangun sebanyak lima lokasi yaitu F1 HP 2000, F1 HP 2001 s.d 2005, F1 HP 2006 s.d 2009, F1 HP 2010 s.d 2012, F1 HP 2013, danF1 HP 2014, 2015.Kebun pengujian pendahuluan terbangun delapan lokasi yaitu UP/1/93, UP/2/94, UP/3/96, UP/4/98, UP/5/99, UP/6/01, UP/7/04 dan UP/8/12.Kebun pengujian lanjutan terbangun sebanyak delapan lokasi yaitu UL/14/97, UL 15/99, UL/16/99, UL/17/99, UL/18/02, UL/21/04, UL/OB/04, UL/22/05. Kebun penggujian adaptasi terbangun tiga lokasi yaitu UA/1/05, UA2/05, UA/3/10. Siklus perakitan klon unggul membutuhkan waktu yang lama (±30 tahun) dan biaya yang besar (Rp. 0,77 milyar) yaitu biaya dikebun persilangan buatan Rp. 30,5 juta, di kebun F1 Rp. 77,2 juta, di kebun pengujian pendahuluan Rp. 209,9 juta, dikebun pengujian lanjutan Rp. 219,7 juta, dan di kebun pengujian adaptasi Rp. 230,4 juta. The assembly of superior rubber clones has been continuously carried out since the 1980s at the Rubber Research Center, Sungai Putih. The assembly technique is done conventionally with natural and artificial crosses, selection, preliminary testing, follow-up testing, and adaptation testing. This assembly aims to get clones that have potential results and better agronomic properties than current clones. The superiority of a clone is determined by its genetic factors and was expressed in morphological forms, anatomical arrangements and physiological processes that support growth, production and adaptability to the environment. In the last ten years (2006 to 2015), the total number of flowers crossed was 224,248 flowers, with total F1 genotypes of 2,451. F1 Gardens were built in five locations such as F1 HP 2000, F1 HP 2001 to 2005, F1 HP 2006 to 2009, F1 HP 2010 to 2012, F1 HP 2013, and F1 HP 2014 to 2015. Preliminary testing plant were built in eight locations such as UP / 1/93, UP / 2/94, UP / 3/96, UP / 4/98, UP / 5/99, UP / 6/01, UP / 7/04 and UP / 8/12. The advanced testing plant were built in eight locations, such as UL / 14/97, UL 15/99, UL / 16/99, UL / 17/99, UL / 18/02, UL / 21/04, UL / OB / 04, UL / 22/05. Adaptation testing plant were built in three locations such as UA / 1/05, UA2 / 05, UA / 3/10. The superior clone assembly cycle requires a long time (± 30 years) and requires a large cost (Rp. 0.77 billion), consisting of Rp. 30.5 million for an artificial crossing garden, Rp. 77.2 million for F1 garden , Rp. 209.9 million for preliminary testing garden, Rp. 219.7 million for further test plantation, and Rp. 230.4 million for adaptation testing in the garden.
APA, Harvard, Vancouver, ISO, and other styles
5

Kheder, Mouhammad, Farhad Ravandi, Hagop Kantarjian, et al. "Higher Bone Marrow Lymphocyte Percentage 3 to 6 Month After Therapy with Hypercvad + Dasatinib Than That with Hypercvad + Imatinib or Hypercvad Alone In Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia." Blood 116, no. 21 (2010): 4336. http://dx.doi.org/10.1182/blood.v116.21.4336.4336.

Full text
Abstract:
Abstract Abstract 4336 Background: Recent reports have suggested that aside from the tyrosine kinase inhibitory effect, dasatinib also promotes a clonal expansion of cytotoxic T-cells in patients with Philadelphia-chromosome positive (Ph+) leukemias. We sought to determine whether there is an absolute lymphocytosis in patients with Ph+ Acute Lymphocytic Leukemia (ALL) treated at our institution on 3 consecutive protocols. Method: We collected data on 122 patients with Ph+ ALL treated with 3 different regimens (hyperCVAD, hyperCVAD + imatinib, and hyperCVAD + dasatinib) from 1994 to 2010, who achieved a complete hematological response (CHR). We examined potential differences between the absolute numbers lymphocytes in peripheral blood (PB) and percentage lymphocytes in bone marrow (BM) at 3 stages: pretreatment, at CHR, and 3–6 months after CHR. Result: Thirty four (28%) patients received hyperCVAD, 43 (35%) hyperCVAD + imatinib, and 45 (37%) hyperCVAD + dasatinib. Twenty five (74%) of patients treated with hyperCVAD, 14 (33%) of patients treated with hyperCVAD + imatinib, and 5 (11%) of patients treated with hyperCVAD + dasatinib have relapsed on these sequential studies. The median PB absolute lymphocyte count for the 3 groups are as follow: Pretreatment: hyperCVAD: 3570.5/uL, hyperCVAD + imatinib: 2262/uL, hyperCVAD + dasatinib: 2376/uL (p = 0.1); at CR: hyperCVAD: 291.5/uL, hyperCVAD + imatinib: 168/uL, hyperCVAD + dasatinib: 239/uL (p = 0.3); 3 to 6 months after CR: hyperCVAD: 485/uL, hyperCVAD + imatinib: 450/uL, hyperCVAD + dasatinib: 632.5/uL (p = 0.26). The median BM lymphocyte percentages are as follow: Pretreatment: hyperCVAD: 3%, hyperCVAD + imatinib: 6%, hyperCVAD + dasatinib: 5% (p = 0.5). CHR: hyperCVAD: 6%, hyperCVAD + imatinib: 4%, hyperCVAD + dasatinib: 4% (p = 0.4). Three to 6 months after CHR: hyperCVAD: 5%, hyperCVAD + imatinib: 3%, hyperCVAD + dasatinib: 7% (p = 0.005). We then divided all patients by their 3 to 6 month BM lymphocyte percentages to 3 groups (< 3%, 3–6%, >6%). There was no difference in remission-free survival for these 3 groups (p=0.76)(Figure 1) Conclusion: Patients who received hyperCVAD + dasatinib had a statistically significant higher BM lymphocyte percentages, 3 to 6 month after achieving CHR than patients treated with the imatinib-containing regimen or chemotherapy alone. Whether this is a clonal population of effector T-cells and whether it plays an important role on the activity of dasatinib compared to imatinib or chemotherapy alone will need to be further investigated. Disclosures: Ravandi: Novartis: Honoraria, Speakers Bureau; Bristol- Myere- Squibb: Honoraria, Research Funding. Kantarjian:BMS, Pfizer and Novartis: Research Funding; Novartis: Consultancy. Cortes:Bristol Myers Squibb: Research Funding; Novartis: Research Funding; Pfizer: Consultancy, Research Funding. O'Brien:Novartis: Research Funding; BMS: Research Funding. Thomas:Novartis: Honoraria; Bristol-Meyer-Squibb: Honoraria; Amgen: Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
6

Odenike, O., J. E. Godwin, K. van Besien, et al. "Phase II trial of decitabine in myelofibrosis with myeloid metaplasia." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7088. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7088.

Full text
Abstract:
7088 Background: DNA hypermethylation of promoter-specific CpG islands has been implicated in the pathogenesis and progression of disease in MMM. We are evaluating Decitabine, a DNA methyltransferase inhibitor in patients (pts) with MMM. Methods: This is a single stage Phase II trial: planned accrual of 20 pts. Pts had to have MMM with anemia and/or splenomegaly. Decitabine is given subcutaneously (SQ) at a dose of 0.3 mg/kg/d on days 1–5, and days 8–12; cycles are repeated every 6 weeks, in the absence of dose limiting toxicities. Response is determined every 12 weeks as an improvement in cytopenias and/or splenomegaly. CD34+ cells are measured by flow cytometry in peripheral blood at baseline, and at days 5 and 12 of therapy; elevated levels are associated with advanced stage and evolution to blast phase in MMM. Results: Pt characteristics: M/F: 6/4, median age 67 (range 42–89), median absolute CD34+ cell count 116 × 106/L (11–4,959), Dupriez score of 2, 1 and 0 in 50%, 30% and 20% respectively. Median number of cycles administered: 3 (range 1- 9). Median WBC and platelet (plt) count: 5.2 K/uL (1.5–29), and 171 K/uL (47–465 K/uL); 5 pts were red cell transfusion dependent. Grade 4 neutropenia (ANC) occurred in all pts, and grade 3/4 plts in 6 pts. 7 pts have developed febrile neutropenia. Grade 3–4 non-hematologic toxicities include a variceal bleed in a patient with baseline portal hypertension and a splenic infarct occurring in another pt. 7 pts are evaluable for response: 3 pts have responded including 1 pt with a CR (normalization of blood counts and transfusion independence), and 1 pt with a PR (Hb increase of > 2 g/dL). A third pt in the blast phase of the disease had a hematological improvement as evidenced by a normalization in plts (from 62 K/uL to 219 K/uL) associated with a significant decrease (from 2.58 K/uL to 0.03 K/uL) in circulating blasts. The other 4 pts have had stable disease. There was a reduction in CD34+ levels: mean decrease of approximately 75% at day 12 of therapy (p<0.0001). Conclusions: Low dose SQ decitabine is feasible in MMM and is associated with a significant decrease in CD34+ cells. There is preliminary evidence of clinical activity. Myelosupression is significant, though reversible and requires close monitoring. These findings must be validated in a larger group of pts. Sponsored by NCI grant NO1-CM-62201 No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
7

Odenike, Olatoyosi M., John E. Godwin, Koen van Besien, et al. "Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia." Blood 108, no. 11 (2006): 4923. http://dx.doi.org/10.1182/blood.v108.11.4923.4923.

Full text
Abstract:
Abstract DNA hypermethylation of promoter-specific CpG islands is a well known mechanism of epigenetic silencing, and has been implicated in the pathogenesis and progression of disease in MMM. We are evaluating 5-aza-2′deoxycytidine (Decitabine), a potent DNA methyltransferase inhibitor in a Phase II trial in patients (pts) with MMM. Decitabine was administered subcutaneously at a dose of 0.3mg/kg/d on days 1–5, and days 8–12 and cycles were repeated every 6 weeks, in the absence of dose limiting toxicities. Response was determined every 12 weeks, and defined as an improvement in cytopenias and/or splenomegaly. Pts who had no response after 2 cycles were eligible for dose escalation to 0.4mg/kg/d. Elevated levels of circulating CD34+ cells are associated with advanced stage and evolution to the blast phase of the disease in MMM. Therefore, CD34+ cells were measured in peripheral blood at baseline, and at days 1, 5 and 12 of the first 2 cycles of therapy as a surrogate marker of disease activity. Seven pts (5 males, 2 females) have been enrolled, median age 71 (range 42–89), median baseline absolute CD34+ cell count 27× 106/L (11–4959), Dupriez score of 2, 1 and 0 in 72%, 14% and 14% respectively. Median number of cycles administered was 4 (range 1–7). Median WBC and platelet (plt) count at baseline were 3.6K/uL (range 1.5–29), and 188K/uL (range 62–446K/uL) and 3 pts were red cell transfusion dependent. Grade 4 neutropenia (ANC) occurred in all pts, and grade3/4 thrombocytopenia in 5 pts. Nadir ANC and plts occurred at a median of 31 days (range 24–44) and 23 days (range 17–31) respectively. Recovery to ANC &gt;0.5K/uL and plts &gt;50K/uL occurred at a median of 43 (range 35–58) and 26 days (23–36) respectively. Two pts required a dose reduction for prolonged myelosuppression, and in 1 pt the dose was escalated to 0.4mg/kg/d for lack of a response after 2 cycles. Two pts have developed febrile neutropenia; one of these pts had a documented infection. Grade 3–4 non-hematologic toxicities were rare and include a variceal bleed in a patient with baseline portal hypertension, occurring in the setting of a platelet count of 486K/uL. There have been no injection site reactions. Five pts are evaluable for response. Of these, two pts have had a response including 1 pt with a CR (normalization of blood counts including transfusion independence). One pt in the blast phase of the disease has had a hematological improvement as evidenced by a normalization in platelet counts (from 62K/uL to 200K/uL) associated with a significant decrease (from 2.58K/uL to 0.03K/uL) in peripheral circulating blasts. The other 3 pts have had stable disease; 2 of these remain on treatment and have received 4 and 7 cycles of treatment, respectively. A trend towards a decrease in spleen size has been observed in 3 of 4 patients with palpable splenomegaly at baseline. Overall, there was a significant reduction in circulating CD34+ levels, with a mean decrease of approximately 70% at day 12 of cycles 1 and 2 (p=0.01) We conclude that low dose decitabine administered subcutaneously is feasible in MMM and is associated with minimal non-hematologic toxicity. Myelosupression is significant, though reversible and requires close monitoring. To our knowledge this is the first report demonstrating the potential clinical activity of decitabine in MMM. This observation requires confirmation in a larger group of patients, and accrual is ongoing to this multi-center Phase II study.
APA, Harvard, Vancouver, ISO, and other styles
8

Tesfaye, Biniyam, Kate Sinclair, Sara E. Wuehler, Tibebu Moges, Luz Maria De-Regil, and Katherine L. Dickin. "Applying international guidelines for calcium supplementation to prevent pre-eclampsia: simulation of recommended dosages suggests risk of excess intake in Ethiopia." Public Health Nutrition 22, no. 3 (2018): 531–41. http://dx.doi.org/10.1017/s1368980018002562.

Full text
Abstract:
AbstractObjectiveTo simulate impact of Ca supplementation on estimated total Ca intakes among women in a population with low dietary Ca intakes, using WHO recommendations: 1·5–2·0 g elemental Ca/d during pregnancy to prevent pre-eclampsia.DesignSingle cross-sectional 24 h dietary recall data were adjusted using IMAPP software to simulate proportions of women who would meet or exceed the Estimated Average Requirement (EAR) and Tolerable Upper Intake Level (UL) assuming full or partial adherence to WHO guidelines.SettingNationally and regionally representative data, Ethiopia’s ‘lean’ season 2011.SubjectsWomen 15–45 years (n 7908, of whom 492 pregnant).ResultsNational mean usual Ca intake was 501 (sd 244) mg/d. Approximately 89, 91 and 96 % of all women, pregnant women and 15–18 years, respectively, had dietary Ca intakes below the EAR. Simulating 100 % adherence to 1·0, 1·5 and 2·0 g/d estimated nearly all women (>99 %) would meet the EAR, regardless of dosage. Nationally, supplementation with 1·5 and 2·0 g/d would result in intake exceeding the UL in 3·7 and 43·2 % of women, respectively, while at 1·0 g/d those exceeding the UL would be <1 % (0·74 %) except in one region (4·95 %).ConclusionsMost Ethiopian women consume insufficient Ca, increasing risk of pre-eclampsia. Providing Ca supplements of 1·5–2·0 g/d could result in high proportions of women exceeding the UL, while universal consumption of 1·0 g/d would meet requirements with minimal risk of excess. Appropriately tested screening tools could identify and reduce risk to high Ca consumers. Research on minimum effective Ca supplementation to prevent pre-eclampsia is also needed to determine whether lower doses could be recommended.
APA, Harvard, Vancouver, ISO, and other styles
9

Soba, Erika, Marjan Budihna, Lojze Smid, et al. "Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy." Radiology and Oncology 49, no. 4 (2015): 365–70. http://dx.doi.org/10.2478/raon-2014-0048.

Full text
Abstract:
AbstractBackground.The aim of the study was to investigate how the expression of tumor markers p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31 influenced the outcome of advanced inoperable oropharyngeal carcinoma patients, treated with concomitant radiochemotherapy.Patients and methods.The pretreatment biopsy specimens of 74 consecutive patients with inoperable stage IV oropharyngeal squamous cell carcinoma treated with concomitant radiochemotherapy were in retrospective study processed by immunochemistry for p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31. Disease-free survival (DFS) was assessed according to the expression of tumor markers.Results.Patients with a high expression of p21 (≥10%), p27 (>50%), Ki-67 (>50%), CD31 (>130 vessels/mm2) and low expression of p53 (<10%), cyclin D1 (<10%) and EGFR (<10%) (favorable levels - FL) had better DFS than patients with a low expression of p21 (<10%), p27 (≤50%), Ki-67 (≤50%), CD31 (<130 vessels/mm2) and high expression of p53 (≥10%), cyclin D1 (≥10%) and EGFR (≥10%) (unfavorable levels - UL). However, statistical significance in survival between FL and UL was achieved only for p27 and cyclin D1. DFS significantly decreased with an increasing number of markers with an unfavorable level per tumor (1–4 vs. 5–7) (78% vs. 32%, respectively; p = 0.004). The number of markers per tumor with UL of expression retained prognostic significance also in multivariate analysis.Conclusions.Statistical significance in survival between FL and UL emerged only for p27 and cyclin D1. The number of markers per tumor with UL of expression was an independent prognostic factor for an adverse outcome.
APA, Harvard, Vancouver, ISO, and other styles
10

Shah, Dhaval, Siayareh Rambally, Martha Mims, and Mark M. Udden. "Romiplostim: A Bridge To Splenectomy In Three Patients With Refractory Immune Thrombocytopenia (ITP)." Blood 122, no. 21 (2013): 4763. http://dx.doi.org/10.1182/blood.v122.21.4763.4763.

Full text
Abstract:
Background Ten to thirty percent of patients with immune thrombocytopenia (ITP) do not respond to initial therapy. Options for such patients include Rituximab, TPO-mimetic agents and splenectomy. We report on three patients with refractory ITP and significant thrombocytopenia who received romiplostim as a bridge to splenectomy. Methods Three patients with isolated ITP or Evans syndrome did not respond to steroids, intravenous immune-globulin (IVIG) or Rituximab. Romiplostim was given to increase the platelet count prior to laparoscopic splenectomy. Before surgery the bone marrow was evaluated and patients were vaccinated. We reviewed their baseline clinical characteristics, and clinical course. Results Patient 1: 51 y/o M presented with fatigue and melena. Laboratory data showed hemoglobin (Hgb) of 7.9 g/dl, platelet (plt) count of < 2,000/uL, LDH of 997 U/L, reticulocyte count of 7.5 % and positive direct Coombs test. Prednisone and IVIG were started with improvement in Hgb but plt count remained < 2000/uL. Rituximab was started on day 7 with no response in plt count after 4 doses. Weekly romiplostim was started on day 37 with no response after 3 doses and then pt was lost to follow up. He presented two months later with plt count of < 2,000/uL and was treated with IVIG with transient response and restarted on Romiplostim. Plt count reached to 93,000/uL with a dose of 6 mcg/kg of romiplostim. He was maintained on romiplostim for a total of 19 doses and then underwent laparoscopic splenectomy. Platelet counts pre-op were 294,000/uL, post-op rose to 1,261,000/uL but normalized afterwards and he has been off all treatment for more than two years (figure 1). Patient 2: 28 y/o F presented with bruising and plt count of 12,000/uL. She was treated with 5 days of dexamethasone with transient improvement in plt count to 50,000/uL which rapidly dropped to < 2,000/uL. Despite daily prednisone and IVIG, plt count continued to be < 2000/uL and weekly rituximab was started on day 7. On day 14, plt count continued to be <10,000/uL and weekly romiplostim was initiated at 1 mcg/kg and increased weekly for four weeks when the plt count reached 61,000/uL after receiving 4 mcg/kg. Patient then underwent laparoscopic splenectomy. Post-op platelet count increased to 1,053,000/uL which returned to normal afterwards and remained so off all treatment at nine months follow up after splenectomy. Patient 3: 66 y/o M with coronary artery disease and long standing ITP was on prednisone 10-20 mg/day with plt count of 10-20,000/uL. Because of side effects of steroids, he was treated with danazol and rituximab (6 weeks) with no response in plt count. Cardiac catheterization prior to splenectomy could not be done because of thrombocytopenia. Romiplostim was then started at dose of 1 mcg/kg and advanced weekly to 3 mcg/kg with improvement in counts to 60,000/uL with peak of 200,000/uL. Cardiac catheterization was normal and he underwent successful laparoscopic splenectomy. Plt count before splenectomy was 73,000/uL and increased to 513,000/uL post-op. The plt count decreased to 120,000/uL and has remained stable for more than two years without further treatment. Conclusions Rituximab and TPO-mimetic agents are increasingly used for treatment of relapsed, refractory ITP as an alternative to splenectomy. Rituximab has a significant relapse rate. TPO-mimetic agents are expensive, require lifelong use, and are associated with rebound thrombocytopenia in those who stop treatment. Long-term use has also been associated with reversible bone marrow fibrosis and thromboembolism. Laparoscopic splenectomy is a safe procedure that is ideally done after a platelet response to high dose steroids and/or IVIG to reduce bleeding risk. Two of our patients were refractory to Rituximab. One received Rituximab concurrently with Romiplostim. All 3 patients did not want long term treatment with a TPO agent and had low platelet counts that were an impediment to surgery. We found that a short course of Romiplostim increased the platelet counts enough to enable surgery. All 3 patients achieved sustained remissions requiring no further treatment. No rebound thrombocytopenia was observed after stopping Romiplostim and none of the patients had bleeding or thrombotic complications. This case series suggests that a short course of Romiplostim can be used safely and effectively as a bridge to splenectomy for patients with refractory ITP. Disclosures: No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "QU 7.5 UL"

1

Vinh-Thang, Hoang, Qinglin Huang, Adrian Ungureanu, Mladen Eić, Do Trong-On, and Serge Kaliaguine. "Effect of the acid properties on the diffusion of C 7 hydrocarbons in UL-ZSM-5 materials." Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-196788.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vinh-Thang, Hoang, Qinglin Huang, Adrian Ungureanu, Mladen Eić, Do Trong-On, and Serge Kaliaguine. "Effect of the acid properties on the diffusion of C 7 hydrocarbons in UL-ZSM-5 materials: Effect of the acid properties on the diffusion of C 7 hydrocarbons inUL-ZSM-5 materials." Diffusion fundamentals 2 (2005) 110, S. 1-2, 2005. https://ul.qucosa.de/id/qucosa%3A14449.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "QU 7.5 UL"

1

Conference on Directions and Strategies of Agricultural Development in the Asia-Pacific Region (1988 Taipei, Taiwan). Conference on Directions and Strategies of Agricultural Development in the Asia-Pacific Region =: [Ya Tai di qu nong ye fa zhan fang xiang yu ce lüe hui yi] : January 5-7, 1988. Institute of Economics, Academia Sinica, 1988.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "QU 7.5 UL"

1

Musteata, M., V. Musteata, A. Dinu, et al. "Acylation of fatty acids with amino-alcohols on UL-MFI type materials." In Recent Progress in Mesostructured Materials - Proceedings of the 5th International Mesostructured Materials Symposium (IMMS2006), Shanghai, P.R. China, August 5-7, 2006. Elsevier, 2007. http://dx.doi.org/10.1016/s0167-2991(07)80378-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"T cu im rre e n tl Sycahleeasd ) qu aas rte wreeldlaatst he thLeammounltt -i D na oth io e n rt aylEIaR rt I h , odtrhoeurgm ht ajporrem di ocd ti eolnprw ob il llem re s q . u T ir hee the resolution of hOabvseearnva im to p ry o rt oafntCcooluupm le bdiamoUdneilvecrosm ity p . onTehnet, sea lt ehfo fo urgthsp ex hteernes , io onntaogfloorbeaclasdto in mga , in boatnhdth th eseeaorcee dva saonlnacn es diantcm lu odse ­ m in acn lu ydeodf ( t C he a rs toyn pe 1s9o 98 f ) m . ethods discussed above are uomciesamnatacnhdbaettmwoesepnhtehree . fl Fuo xe rsmaatntyhearbeoaus, n d th atr io ie nsoofftthhee rep F li o ca rtE in NgSaOn , d c , ur in re nstom co eupclaesdesm , oidmep ls roav re in cgapoanb le thoefo of frtehaelsie st iwcillalnrde -q suuirrfeacse ig coupling may be ess eenatd ia dli . tiA on ll tshue cc ecsusrroefnetmgpein ri ecraalt / isotn at i o st ficcaolumpe le th dom ds o . dFeo ls rirnesptlain ca ctee , a model parameterisatio nificant improvements in the SST anomaly patterns in the equatorial Pacific that th ry elraeyqeu rs ir , ecd lo m ud osd , erlad im inasp ti oonf , saun rf dacceonpv ro ecce ti sosn es, bound­ have many characteristics in common with observed to a quick solution, but, ro g v iv eemnetnhtesiam re p o li rktealny . N to onye ie o ld flEeN ss SsO uc cceosm sf puolsiin te tsh . eCm ur orreentdim ffi ocduelltspa ro re blceomnso id ferreapblliy ­ imp Iatcsthoofud ld ronuogthbte , they are worth pursuing. ce of the p ca hteirnigcc th ir ecuslpae ti c o if n ic peav tt oelruntsioinnoafgtihve en SESNTSaOndepaitsm od oes . ­ tehxe prospects for im forgotten, however, that not all of However, it is precisely this problem that must be no ctlufsuilv ly eluynodnersse ta a n so pnraolvteidmde ro sc uag le hst . p A re l dictions reside solved. Just as the ‘average’ daily weather is rarely of climate variabilit d y , th th eem re u l is ti aanmnpulaelteo th doeucgahdawles ca dloeo ce bpsteuravleda , idthteo ‘ ucnadneornsitcaanl’ diEnNgS th Oan id aeauissefm ul orceonastcroun ct ­ e2x .1 is c t ) e nc aend -e th .g e . , sien the time series o vidence for its for prediction. To reach their full potential, coupled distributions of rai cnuflaalrl ( cFhiagnugrees2i . n2ftrhae in f p al rlob (F ab ig il uir ty eim nd oidveildsun al eepdas to t E be N S ab O le etpoisroedpe li scaa te ndt he th eeivroleuv ti ooln vi nogfnoefw co duep velopments in data an ). Very recently, extratropical atmospheric and ocean interactions. There is lesdommeoedveildsehnacveeosftd ar etaeld ys t is oaonpdeinn the accuracy The most optimistic expectation is that once that may have a somewhat c ad d a if lfv er aern ia t t io unpstihnisEN fie S ld O . cEoNuSpO le , d th m ey odw el i s ll bheavaeb le cotnoqhueelrped id etnhtei fy chaanld le npg re edio ct ftmheeasiun red by the ocean s character, as other modes of climate variability. This may include Zhang te ertananl. ua1l99 ti 7 m , eFoslc la al neusr fa ( cKeleteemmapne ra et tures, from links between ENSO and the climate system not yet are now beginning to fin ddeatanlu . m1b9e9r8 ) o . M al. od1e9 ll 9e6 rs , m dis ocdoevlesremdaiyntahiediimnpienrv fe ecsttiogbaste io rv nast io onfaplodsastiab . lIemcplriomvaetdem ab e il cih ty anoin sm th seinde th ca edN al otrothmaun lt d i tropic f potential modes that link ocean basins, such as ENSO-and Barnett 1996). There is adlescoad ev aalltiPm ac eifsiccaf le o r ( vari­ related variations of SST in the tropical North Atlantic, ENSO links to rainfall may come an id dengcoed th ep aetnsLoam ti e f rece In n tl aydddiistc io u n ss etdoboycE ea n n fi -e altdmaonsdphMea re y er c o ( u1p9l9 in 7 g ). , new nointutdheeo se fcE ul N ar S O va riitas bility in the str ding generations of models need to include realistic land-southern Europe (R eolpfe -le wes .g k . i , a in ndneonrg Ha th th lp e e rn an dAfm ri acga/ ­ rae tm ali oss ti pchm er oedeclosuopflitnhge . la Snudch su rifm ac peroavnedmie ts ntvsegientvao ti lovneaThheeadp , r m ed aiyctaalbsio lity of ENS rt 1987). and adequate descriptions based on observed data of in Northern Hevm ar iyspohnerdeecOa sp d , rail on ntgiem ( e to s Ba c a ls a a le fse , w e sp se eacs ia oln ly strheep re isne it nitaal tio ve nge in ta t m io ondesltsa te is . c W ur orrekn tl oynbleainndg -s m ur afiancleym 19 e9a5n ) s . (i I . n e ., additio meda et al. driven by the development of coupled models for over several cdheacnagdenes , sis ) n ec a th u lso e la r ‘ itvnyfpairciaalbio li rty in the climate climate change projection over the next century conditional ENSO probability l u fo ernecceassetsxsi . m pe Fpcolteeds ’ e values (Dickinson et al. 1996). the Gulf Coast of the United States shows reaxaam sonal Significant advances in coupled model-based ENSO signal for both the first and second half s o tro p n le, f th g e." In Droughts. Routledge, 2016. http://dx.doi.org/10.4324/9781315830896-45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"e. The transfer basket containing the items to be cleaned was lowered into the immersion sump , and statically (i.e. no liquid flow) sonicated for a finite pe-riod of time, usually 15 minutes. f. After static sonication, the rinse pump was turned on and the liquid in the immersion bath was circulated through the activated carbon columns at a rate of1,700 ml/minute for a finite period of time. The circulation time ranged fro m 15 minutes to 2 hours, depending on the purpose of the test. g. The rate of decontamination was monitored by following the concentration of the contaminant in the decontamination liquid (HFE-7100). h . Steps e and f were repeated until the presence of contaminant in the circulat-ing liquid could no longer be detected. i. When the immersion sump liquid was free of contaminant, the transfer basket was moved from the immersion sump to the superheat sump and dried for 30 minutes to remove liquid drag out. j . The transfer basket was removed from the Poly-Kleen™ system. The test pieces were removed from the basket, visually examined, photographed under visible and UV light, reweighed, and archived. I n order to maximize ultrasonic power density, the minimum amount of liquid needed to cover the parts being cleaned was used. Typically, the sump contained from 130 to 180 mm (5 to 7 inches) of liquid, which corresponds to a liquid vol-ume of approximately 15 liters to 30 liters (4 to 8 gallons) and a corresponding ul-trasonic power density of 26 to 18 watts/liter (100 to 70 watts/gallon). In prelimi-nary tests, it was noted that immersing and sonicating the test samples when the immersion sump was filled to the brim (about 53 liters (14 gallons)) did not result in effective cleaning. At that volume, the ultrasonic power density had dropped to a value of 8 watts/liter (30 watts/gallon). While this value would be considered marginal in a stainless steel ultrasonic bath, where the ultrasonic waves can be re-flected from the walls back into the liquid, in a polypropylene bath in which the walls absorb rather than reflect the ultrasonic waves, this power density level is too low. If parts were also contaminated with biological agents, after Step h, they would be sonicated in a fluorinated surfactant/HFE-7100 solution that would be circu-lated through microfilters to remove suspended materials. The parts would then be rinsed in fresh HFE-7100 to remove fluorocarbon surfactant residues, and then dried as described above. Table 3 lists the sensitive equipment decontamination experiments that were carried out in the Poly-Kleen™ system during the course of the program. The combination of equipment processed, contaminants used, and monitoring method(s) examined are listed in this table. The results of the various cleaning re-sults are summarized in Table 4. This table records the weights of the items listed in Table 3, before and after contamination, as well as the post-cleáning weight and visual appearance of these items." In Surface Contamination and Cleaning. CRC Press, 2003. http://dx.doi.org/10.1201/9789047403289-19.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "QU 7.5 UL"

1

Takahashi, Y., M. Kalafatis, J. P. Girma, and D. Meyer. "ABNORMALITY OF THE N-TERMINAL PORTION OF VON WILLEBRAND FACTOR (FRAGMENT Sp III ) IN TYPE IIA AND IIC VON WILLEBRAND DISEASE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644645.

Full text
Abstract:
A new analytical method was established, allowing the characterization of von Willebrand Factor (vWF) degradation fragments from minute amounts of plasma without the need for immunopurification of vWF. Ten ul of citrated plasma in 20 ul of 0.1 M Tris-HCl, pH 7.8, 0.1 M NaCl, 10 mM EDTA buffer were treated with S. aureus V-8 protease for 15 min to 3 h at 22°C. Following addition of 1 mM DFP, the cleaved fragments were separated by SDS-polyacrylamide or SDS-agarose gel electrophoresis and identified by 125 I-labeled polyclonal or monoclonal antibodies (MAbs) to vWF andautoradiography. Quantification of each fragmentwas estimated by counting radioactivity in slices of the dry gel. In normal plasma, S. aureus V-8 protease produced two dimeric fragments of vWF, with identical electrophoretic and antigeniccharacteristics to those produced from highly purified vWF, ie a C-terminal fragment of 220 kd (Spll) and a series of N-terminal fragments (Spill) with a major species of Mr 320 kd (SpIIIa) and two minor ones of 265 kd (SpIIIb) and 215 kd (SpIIIc). The method was applied to further characterize the molecular abnormalities of vWF in 15 patient plasmas with variant (type II) von Willebrand disease (vWD). In all cases with type IIA, IIB, IIC and IID tested, fragment Spll had the same mobility as in normal plasma. In 7 patients with type IIA, the amount and distribution ofthe three Spill species were clearly abnormal, with a marked decrease or absence of SpIIIa and an increase of SpIIIb and SpIIIc. Results slightly varied between patients but were consistent within one family. In 4 patients with type IIC, the band SpIIIb was lacking. In 2 patients with type IIB and 2 patients with type IID, there was no significant modification of Spill. In all cases the pattern of Spill was similar whether using polyclonal antibodies to vWF or MAbs to Spill.The pattern of normal or abnormal Spill remainedthe same in fresh or frozen plasma and was not modified by the presence of 5 mM EDTA at the timeof blood collection. Furthermore, the abnormaldistribution of Spill in type IIA or IIC vWD wasalready present after the shortest digestion time(15 min) indicating that the fragment Spill was produced from an abnormal vWF during the primary digestion with S. aureus V-8 protease. In conclusion, the molecular abnormality of vWF in type IIA and IIC vWD appears to reside in Spill, the N-terminal portion of the subunit (residues 1 to 1,365).
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography